华润博雅生物制药集团股份有限公司 关于增补非独立董事及第八届董事会战略与 ESG 委员会委员的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 华润博雅生物制药集团股份有限公司（以下简称公司）于 2024 年 11 月 26 日召开了第八届董事会第七次会议，审议通过了《关于增补非独立董事的议案》 《关于增补第八届董事会战略与 ESG 委员会委员的议案》，具体情况如下： 鉴于孙金妮女士因工作调动原因提请辞去公司第八届董事会董事、董事会战 略与 ESG 委员会委员职务，根据《公司章程》有关规定，公司董事会成员为九人， 公司将增补一名董事。经公司董事会提名、薪酬与考核委员会任职资格审查后， 公司董事会提名任辉先生为公司非独立董事候选人（简历详见附件）,任期自股 东大会审议通过之日起至第八届董事会届满之日止。 证券代码：300294 证券简称：博雅生物 公告编号：2024-075 为保障董事会专门委员会规范运作，根据相关法律法规，公司董事会提名任 辉先生当选公司董事，并增补其为董事会战略与 ESG 委员会委员，任期自股东大 会审议通过其当选董事之日起至第八届董事会届满之 ...

（二）会议召集人：公司董事会。（经公司第八届董事会第七次会议审议通 过，决定召开本次股东大会） 证券代码：300294 证券简称：博雅生物 公告编号：2024-076 华润博雅生物制药集团股份有限公司 关于召开 2024 年第四次临时股东大会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、召开会议基本情况 （一）大会届次：2024 年第四次临时股东大会。 （三）会议召开的合法、合规性：召集程序符合有关法律、行政法规、部门 规章、规范性文件和《公司章程》的规定。 （四）会议召开时间：2024 年 12 月 12 日上午 09:30。 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2024 年 12 月 12 日上午 9:15-9:25，9:30-11:30，下午 13:00—15:00；通过互联网投票 系统投票的时间为 2024 年 12 月 12 日上午 9：15—下午 15:00 期间的任意时间。 （五）会议召开方式：现场投票和网络投票相结合的方式。 现场投票：股东本人出席现场会议或通过授权委托书（见附件 2）委托他人 出席； 网络投票 ...

华润博雅生物制药集团股份有限公司 内部审计制度 （经公司于 2024 年 11 月 26 日召开的第八届董事会第七次会议审议通过） 第一章 总则 第一条 为规范和加强华润博雅生物制药集团股份有限公司（以下简称华润博雅生 物或公司）内部审计工作，有效贯彻落实中央重大决策部署、国家政策措施、国资监管 及华润博雅生物相关管理要求，实施华润博雅生物战略规划，遵循境内外法律法规和华 润博雅生物规章制度，不断规范经营行为、防范和降低经营风险、提升经营效率和效果， 实现高质量发展，根据《中华人民共和国审计法》《审计署关于内部审计工作的规定》 《关于深化中央企业内部审计监督工作的实施意见》《中央企业内部审计管理暂行办法》 《中国内部审计准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市 公司自律监管指引第 2 号--创业板上市公司规范运作》等有关法规制度，结合华润博雅 生物实际情况，修订本制度。 第二条 本制度适用于华润博雅生物及其分子公司。 第三条 本制度所称内部审计，是指公司内部独立、客观的监督、评价和咨询活动， 通过运用系统、规范的方法，审查评价中央重大决策部署、国家政策措施、国资监管要 求落实、战略执行、 ...

特别提示： 1、本次申请解除限售股份为华润博雅生物制药集团股份有限公司（以下简 称公司）向特定对象华润医药控股有限公司发行的 78,308,575 股份，本次解除限 售股份数量为 78,308,575 股，占公司总股本的 15.5298%；本次解除限售后实际 可上市流通的股份数量为 78,308,575 股，占公司总股本的 15.5298%。 2、本次限售股份可上市流通日：2024 年 11 月 25 日（星期一）。 一、公司发行股份概况 证券代码：300294 证券简称：博雅生物 公告编号：2024-073 华润博雅生物制药集团股份有限公司 关于向特定对象发行股票解除限售上市流通的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 2021 年 10 月 26 日，公司收到中国证券监督委员会（以下简称中国证监会） 出具的《关于核准博雅生物制药集团股份有限公司向特定对象发行股票注册的批 复》（证监许可[2021]3340 号），同意公司向特定对象发行股票的注册申请。公 司向特定对象华润医药控股有限公司发行股票 78,308,575 股，本次发行完成后， 公司 ...

关于收购绿十字香港控股有限公司 100%股权进展 暨完成股东变更的公告 证券代码：300294 证券简称：博雅生物 公告编号：2024-072 华润博雅生物制药集团股份有限公司 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 2024 年 11 月 6 日 华润博雅生物制药集团股份有限公司（以下简称公司）于 2024 年 7 月 17 日召开第八届董事会第四次会议，审议通过《关于收购绿十字香港控股有限公司 100%股权的议案》，公司使用自有资金人民币 18.2 亿元协议受让 GREEN CROSS HK HOLDINGS LIMITED（中文名：绿十字香港控股有限公司）100%股权，从而间接收 购境内血液制品主体绿十字（中国）生物制品有限公司。具体内容详见同日在巨 潮资讯网（网址：http：//www.cninfo.com.cn）披露的《关于收购绿十字香港控 股有限公司 100%股权的公告》。 二、进展情况 2024 年 11 月 6 日，公司收到绿十字（香港）发来的《关于完成股东名册变 更登记的函》，获悉绿十字（香港）已完成股东名册的变更登记。根据相关 ...

Investment Rating - The report maintains a "Buy" rating for the company [2][5]. Core Views - The company experienced a significant decline in revenue and profit due to the transfer of stakes in subsidiaries, which are no longer included in the consolidated financials [2][3]. - The blood products segment remains stable, with a slight revenue increase driven by specific factor products, despite a short-term revenue decline in Q3 2024 [3][4]. - The company has achieved a good growth in plasma collection, with a 12.39% year-on-year increase, and is progressing on its smart factory project expected to start trial production by the end of 2025 [4]. Financial Summary - For the first three quarters of 2024, the company reported revenue of 1.245 billion yuan, down 43.16%, and a net profit of 413 million yuan, down 11.07% [2][3]. - The blood products segment generated revenue of 1.089 billion yuan in the first nine months of 2024, a slight increase of 0.39% year-on-year [3]. - The company forecasts net profits of 567 million yuan, 627 million yuan, and 691 million yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 1.12, 1.24, and 1.37 yuan [5][6]. Operational Highlights - The company has successfully optimized the plasma donation environment, leading to a total plasma collection of 387.44 tons in the first three quarters of 2024 [4]. - The smart factory construction is progressing well, with major structural work completed, and it is expected to be operational by July 2027 [4]. Market Performance - The stock has shown a performance decline of 29% over the past year, reflecting broader market trends in the pharmaceutical sector [2].

Investment Rating - The investment rating for the company is "Buy" [4][10]. Core Insights - The company reported a significant increase in plasma collection, achieving a total of 387.44 tons, which represents a year-on-year growth of 12.39% [2]. - Revenue from blood products for the first three quarters of 2024 reached 1.08 billion yuan, a slight increase of 0.39% compared to the previous year, driven mainly by the growth in human prothrombin complex and human factor VIII [2]. - The company has enhanced its plasma collection capabilities through the acquisition of Green Cross (Hong Kong), which indirectly controls Green Cross (China), and is expected to see steady growth in plasma collection due to the stable performance of existing plasma stations and the positive outlook for new stations [2]. - The company has made significant improvements in profitability, with a gross margin of 66.67% and a net margin of 33.12% for the first three quarters of 2024, reflecting an increase of 16.63 percentage points and 11.48 percentage points year-on-year, respectively [3]. - The company is actively advancing its smart factory construction and has ongoing research pipelines that are expected to enhance profitability once approved [2][3]. Financial Summary - For the first three quarters of 2024, the company reported total revenue of 1.245 billion yuan, a decrease of 43.16% year-on-year, and a net profit attributable to shareholders of 413 million yuan, down 11.07% [1]. - The third quarter of 2024 saw revenue of 349 million yuan, a year-on-year decline of 46.21%, but a quarter-on-quarter increase of 21.89% [1]. - The company’s projected net profits for 2024, 2025, and 2026 are 530 million yuan, 576 million yuan, and 630 million yuan, respectively, with corresponding earnings per share of 1.05 yuan, 1.14 yuan, and 1.25 yuan [6].

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - Short-term performance is under pressure, but the plasma collection volume is steadily increasing. In Q3 2024, the company achieved revenue of 3.49 billion yuan, a year-on-year decline of 46.2%, and a net profit attributable to shareholders of 0.97 billion yuan, down 30.0% year-on-year. The core blood products business generated revenue of 10.9 billion yuan from Q1 to Q3 2024, a year-on-year increase of 0.39% [2][3] - The company operates at an industry-leading efficiency level, with significant potential for growth in both plasma collection volume and profit per ton. The recent acquisition of Green Cross is expected to enhance operational capabilities and increase plasma collection volume [2][3] - The company is the only blood product platform under China Resources, which has been providing substantial support in new plasma station applications and resource integration. The strategic position of the company within the China Resources health sector is expected to be significant, with plans to double the number of plasma stations and collection scale during the 14th Five-Year Plan period [3] Financial Summary - For 2024-2026, the company's net profit forecasts have been adjusted to 5.0 billion yuan, 5.6 billion yuan, and 6.3 billion yuan, with year-on-year growth rates of 112.6%, 11.4%, and 12.1% respectively. The current stock price corresponds to P/E ratios of 32, 29, and 26 times [3][4] - The company aims to achieve a revenue of 1.73 billion yuan in 2024, with a year-on-year decline of 34.89%, followed by a recovery in 2025 and 2026 with growth rates of 12.34% and 11.78% respectively [4][5] - The company’s gross margin is projected to be 67.84% in 2024, with a net profit margin of 30.36% [5]

Investment Rating - The report maintains a "Buy" investment rating for the company [1][3]. Core Views - The company has experienced a significant decline in revenue and net profit for the first three quarters of 2024, with revenue at 1.245 billion yuan, down 43.16% year-on-year, and net profit at 413 million yuan, down 11.07% year-on-year. This decline is primarily due to the transfer of stakes in two subsidiaries, which are no longer included in the consolidated financials [1]. - Despite the overall decline, the blood products segment has shown steady growth, with revenue of 1.089 billion yuan for the first nine months of 2024, an increase of 0.39% year-on-year, driven by higher sales of specific blood products [1]. - The company is expanding its plasma collection stations through both organic growth and acquisitions, having increased its plasma collection by 12.39% year-on-year to 387.44 tons in the first nine months of 2024 [1]. - A significant acquisition was made in July 2024, where the company purchased 100% of Green Cross (Hong Kong) for 1.82 billion yuan, which will enhance its plasma collection capabilities and product offerings [1]. - The company is actively developing new products, with the application for the market launch of a 10% intravenous immunoglobulin (IVIG) already accepted, and it is the first in China to receive clinical approval for a C1 esterase inhibitor [2]. Financial Summary - The company forecasts revenues of 1.93 billion yuan in 2024, 2.08 billion yuan in 2025, and 2.24 billion yuan in 2026, with corresponding net profits of 552 million yuan, 599 million yuan, and 655 million yuan respectively [3][5]. - The earnings per share (EPS) are projected to be 1.09 yuan in 2024, 1.19 yuan in 2025, and 1.30 yuan in 2026, with the current stock price reflecting a price-to-earnings (P/E) ratio of 28.8, 26.5, and 24.2 for the respective years [3][5].

比较大的情况下公司依然是在前三季度水池品购物实现了一个正增长同时就是三季度的采江量也达到了384.4吨同比增长了12.4那考虑到江西两个新疆这样的开采以及绿水资本后续的整合我们认为对于未来公司的水池品的主业稳定的持续增长还是坚定看好的一个趋势 那我们今天也非常有幸的请到了公司的总裁梁小民总以及公司副总裁财务总监兼董秘义梁化晨总和大家进行三级道的电话交流那我们今天的交流主要分成三个部分先是由公司的副总裁财务总监兼董秘义梁化晨总对于公司的三级路的经营情况进行介绍再由主持券商和投资者提问那首先有请化晨总 好的各位研究员各位投资者大家下午好那么很高兴今天跟大家一起交流我们博雅生物三季度的一些情况那么对于前三季度我整体跟大家做一个简单的介绍详细的数据我们也已经进行了披露大家应该这两天应该也都做了一些分析和研究 那么前三季度呢 我们整体的营收呢 大概是12.45亿那么直线规模经济刃呢 大概在4.12亿元那么血液制品呢 在收入和利润端呢 均保持呢 这个正增长但是增幅呢 实际上相比于二季度 半年度的时候呢 是有所下降的 所以呢这个时候呢这个我相信大家可能通过分期数的数据也能看到就是我们在三季度呢可能比去年三季度可能存在一定幅 ...